Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

180,861 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Asian race and origin have no clinically meaningful effects on polatuzumab vedotin pharmacokinetics in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.
Shi R, Lu T, Ku G, Ding H, Saito T, Gibiansky L, Agarwal P, Li X, Jin JY, Girish S, Miles D, Li C, Lu D. Shi R, et al. Among authors: li c, li x. Cancer Chemother Pharmacol. 2020 Sep;86(3):347-359. doi: 10.1007/s00280-020-04119-8. Epub 2020 Aug 8. Cancer Chemother Pharmacol. 2020. PMID: 32770353 Free PMC article. Clinical Trial.
Bayesian Population Model of the Pharmacokinetics of Venetoclax in Combination with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Results from the Phase III MURANO Study.
Deng R, Gibiansky L, Lu T, Agarwal P, Ding H, Li X, Kshirsagar S, Lu D, Li C, Girish S, Wang J, Boyer M, Humphrey K, Freise KJ, Salem AH, Seymour JF, Kater AP, Miles D. Deng R, et al. Among authors: li c, li x. Clin Pharmacokinet. 2019 Dec;58(12):1621-1634. doi: 10.1007/s40262-019-00788-8. Clin Pharmacokinet. 2019. PMID: 31209657 Clinical Trial.
Exposure-response analysis of venetoclax in combination with rituximab in patients with relapsed or refractory chronic lymphocytic leukemia: pooled results from a phase 1b study and the phase 3 MURANO study.
Deng R, Gibiansky L, Lu T, Li X, Lu D, Li C, Girish S, Wang J, Boyer M, Shankar N, Humphrey K, Freise KJ, Salem AH, Seymour JF, Kater AP, Miles D. Deng R, et al. Among authors: li c, li x. Leuk Lymphoma. 2020 Jan;61(1):56-65. doi: 10.1080/10428194.2019.1657575. Epub 2019 Sep 24. Leuk Lymphoma. 2020. PMID: 31549889 Clinical Trial.
Population pharmacokinetics and exposure-response analysis of a single dose of sotrovimab in the early treatment of patients with mild to moderate COVID-19.
Sager JE, El-Zailik A, Passarell J, Roepcke S, Li X, Aldinger M, Nader A, Skingsley A, Alexander EL, Yeh WW, Mogalian E, Garner C, Peppercorn A, Shapiro AE, Reyes M. Sager JE, et al. Among authors: li x. CPT Pharmacometrics Syst Pharmacol. 2023 Jun;12(6):853-864. doi: 10.1002/psp4.12958. Epub 2023 Apr 6. CPT Pharmacometrics Syst Pharmacol. 2023. PMID: 36922886 Free PMC article.
Navigated range expansion promotes migratory culling.
Zhang Y, Hu Q, Su Y, Chu P, Wei T, Li X, Liu C, Fu X. Zhang Y, et al. Among authors: li x. Proc Natl Acad Sci U S A. 2024 Dec 10;121(50):e2408303121. doi: 10.1073/pnas.2408303121. Epub 2024 Dec 3. Proc Natl Acad Sci U S A. 2024. PMID: 39625973
180,861 results
You have reached the last available page of results. Please see the User Guide for more information.